Vir Biotechnology Stock Buy Hold or Sell Recommendation
| VIR Stock | USD 6.95 0.21 3.12% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Vir Biotechnology is 'Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vir Biotechnology given historical horizon and risk tolerance towards Vir Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for Vir Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Vir Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide. Note, we conduct extensive research on individual companies such as Vir and provide practical buy, sell, or hold advice based on investors' constraints. Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Vir |
Execute Vir Biotechnology Buy or Sell Advice
The Vir recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vir Biotechnology. Macroaxis does not own or have any residual interests in Vir Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vir Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Vir Biotechnology Trading Alerts and Improvement Suggestions
| Vir Biotechnology generated a negative expected return over the last 90 days | |
| Vir Biotechnology has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B. | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency |
Vir Biotechnology current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vir analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vir analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Vir Biotechnology Returns Distribution Density
The distribution of Vir Biotechnology's historical returns is an attempt to chart the uncertainty of Vir Biotechnology's future price movements. The chart of the probability distribution of Vir Biotechnology daily returns describes the distribution of returns around its average expected value. We use Vir Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vir Biotechnology returns is essential to provide solid investment advice for Vir Biotechnology.
| Mean Return | -0.32 | Value At Risk | -5.81 | Potential Upside | 5.41 | Standard Deviation | 4.28 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vir Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vir Stock Institutional Investors
The Vir Biotechnology's institutional investors refer to entities that pool money to purchase Vir Biotechnology's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Voloridge Investment Management, Llc | 2024-06-30 | 1.2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | D. E. Shaw & Co Lp | 2024-06-30 | 922.6 K | Northern Trust Corp | 2024-09-30 | 878.9 K | Bank Of America Corp | 2024-06-30 | 851.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 813.3 K | Bridgeway Capital Management, Llc | 2024-06-30 | 788.7 K | Sb Investment Advisers (uk) Ltd | 2024-09-30 | 16.7 M | Blackrock Inc | 2024-06-30 | 16.4 M |
Vir Biotechnology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (256.2M) | (3.5M) | (119.0M) | (1.2B) | 116.3M | 122.1M | |
| Change In Cash | 63.5M | 328.7M | (88.1M) | 504.6M | (606.7M) | (576.3M) | |
| Free Cash Flow | (138.6M) | (197.5M) | (69.4M) | 1.6B | (800.4M) | (760.3M) | |
| Depreciation | 4.5M | 5.4M | 5.8M | 6.8M | 19.5M | 20.4M | |
| Other Non Cash Items | 8.9M | 45.2M | (52.6M) | 388.4M | 11.2M | 10.6M | |
| Capital Expenditures | 8.9M | 6.5M | 21.8M | 68.0M | 21.6M | 21.7M | |
| Net Income | (174.7M) | (298.7M) | 528.6M | 515.8M | (615.1M) | (584.3M) | |
| End Period Cash Flow | 122.8M | 451.5M | 363.4M | 868.0M | 261.3M | 363.8M | |
| Change To Netincome | 32.3M | 45.2M | 46.4M | 475.3M | 546.6M | 573.9M |
Vir Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vir Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vir Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vir stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 2.54 | |
σ | Overall volatility | 4.28 | |
Ir | Information ratio | -0.1 |
Vir Biotechnology Volatility Alert
Vir Biotechnology exhibits very low volatility with skewness of 2.39 and kurtosis of 14.96. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vir Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vir Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vir Biotechnology Fundamentals Vs Peers
Comparing Vir Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vir Biotechnology's direct or indirect competition across all of the common fundamentals between Vir Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vir Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vir Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vir Biotechnology to competition |
| Fundamentals | Vir Biotechnology | Peer Average |
| Return On Equity | -0.37 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (91.85) % | (5.51) % |
| Current Valuation | 126.57 M | 16.62 B |
| Shares Outstanding | 137.72 M | 571.82 M |
| Shares Owned By Insiders | 11.84 % | 10.09 % |
| Shares Owned By Institutions | 74.47 % | 39.21 % |
| Number Of Shares Shorted | 5.72 M | 4.71 M |
| Price To Earning | 3.16 X | 28.72 X |
| Price To Book | 0.75 X | 9.51 X |
| Price To Sales | 11.81 X | 11.42 X |
| Revenue | 86.18 M | 9.43 B |
| Gross Profit | 1.03 B | 27.38 B |
| EBITDA | (664.85 M) | 3.9 B |
| Net Income | (615.06 M) | 570.98 M |
| Cash And Equivalents | 2.2 B | 2.7 B |
| Cash Per Share | 16.55 X | 5.01 X |
| Total Debt | 124.54 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 4.79 X | 2.16 X |
| Book Value Per Share | 9.08 X | 1.93 K |
| Cash Flow From Operations | (778.78 M) | 971.22 M |
| Short Ratio | 7.28 X | 4.00 X |
| Earnings Per Share | (3.93) X | 3.12 X |
| Price To Earnings To Growth | 1.14 X | 4.89 X |
| Target Price | 29.5 | |
| Number Of Employees | 587 | 18.84 K |
| Beta | 0.46 | -0.15 |
| Market Capitalization | 928.23 M | 19.03 B |
| Total Asset | 1.92 B | 29.47 B |
| Retained Earnings | (237.82 M) | 9.33 B |
| Working Capital | 1.41 B | 1.48 B |
| Net Asset | 1.92 B |
Note: Disposition of 4397 shares by De Verneuil Vanina of Vir Biotechnology at 10.11 subject to Rule 16b-3 [view details]
Vir Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vir . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vir Biotechnology Buy or Sell Advice
When is the right time to buy or sell Vir Biotechnology? Buying financial instruments such as Vir Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Vir Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.